Premium
CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring
Author(s) -
ALEIL B.,
LÉON C.,
CAZENAVE J.P.,
GACHET C.
Publication year - 2009
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2009.03554.x
Subject(s) - clopidogrel , cyp2c19 , acute coronary syndrome , medicine , percutaneous coronary intervention , pharmacogenetics , drug response , antiplatelet drug , genotyping , pharmacogenomics , pharmacology , drug , cardiology , genetics , genotype , biology , gene , aspirin , cytochrome p450 , metabolism , myocardial infarction